hemotrop
mycoplasma
hemoplasma
noncultiv
epierythrocyt
bacteria
infect
varieti
mammalian
speci
worldwid
recent
year
hemoplasma
attract
scientif
attent
due
host
divers
pathogen
potenti
main
pathogen
featur
hemoplasma
hemolysi
clinic
sign
lethargi
anorexia
pale
mucos
membran
pyrexia
jaundic
pigmenturia
may
present
sever
affect
anim
report
hemoplasma
infect
human
emphas
need
character
agent
detail
felin
hemoplasma
therebi
serv
model
extens
molecular
clinic
character
within
group
organ
felin
hemoplasma
compris
least
three
differ
speci
mycoplasma
haemof
mhf
candidatu
mycoplasma
haemominutum
cmhm
candidatu
mycoplasma
turicensi
cmt
concurr
infect
two
three
hemoplasma
speci
document
suggest
immunolog
crossprotect
exist
felin
hemoplasma
recent
experiment
confirm
mhf
pathogen
three
felin
hemoplasma
speci
induc
sever
hemolyt
anemia
potenti
fatal
left
untreat
contrast
two
felin
hemoplasma
may
induc
mild
anemia
infect
often
remain
subclin
natur
rout
hemoplasma
transmiss
cat
still
unresolv
aggress
interact
bloodsuck
arthropod
mainli
implic
experiment
transmiss
intraperiton
intraven
subcutan
inocul
hemoplasmacontain
blood
success
recent
lowdos
infect
model
mhf
aim
accur
mirror
natur
transmiss
hemoplasma
develop
differ
antibiot
regimen
reduc
hemoplasma
blood
load
allevi
clinic
sign
far
treatment
protocol
success
consist
clear
felin
hemoplasma
infect
limit
emphas
need
investig
protect
immun
mechan
agent
recent
cat
experiment
infect
mhf
cmt
overcam
bacteremia
shown
protect
reinfect
hemoplasma
speci
studi
novacco
et
al
suggest
signific
role
humor
immun
respons
protect
cmt
reinfect
nine
ten
cat
protect
reinfect
show
intermedi
high
antibodi
level
cmt
challeng
furthermor
transient
decreas
antibodi
level
observ
protect
cat
immedi
attempt
reinfect
could
due
bind
antibodi
inocul
antigen
earli
phase
rechalleng
compar
control
group
protect
cat
exhibit
significantli
higher
ratio
lymphocyt
count
pronounc
eosinophilia
therefor
author
conclud
earli
immun
respons
prior
onset
bacteremia
benefici
protect
cmt
reinfect
result
found
studi
hick
et
al
earli
increas
proinflammatori
cytokin
tumor
necrosi
observ
cat
protect
mhf
reinfect
furthermor
immun
respons
seem
skew
toward
respons
primari
mhf
infect
wherea
switch
initi
delay
respons
observ
primari
cmt
infect
result
suggest
cat
respond
infect
differ
felin
hemoplasma
speci
differ
immun
mechan
import
data
immun
respons
elicit
hemoplasma
infect
provid
previou
studi
mechan
confer
protect
reinfect
yet
clarifi
passiv
immun
transfer
humor
immun
nonimmun
individu
form
antibodi
allow
protect
role
antibodi
absenc
cellular
immun
mechan
assess
present
studi
aim
investig
whether
passiv
transfer
antibodi
mhfrecov
recipi
cat
induc
partial
complet
protect
bacteremia
clinic
diseas
follow
homolog
challeng
mhf
differ
paramet
address
humor
cellular
immun
respons
monitor
passiv
immun
control
cat
main
experi
male
specifi
pathogenfre
spf
cat
liberti
research
inc
waverli
new
york
usa
use
recipi
cat
five
adult
spf
cat
serv
blood
donor
three
cat
overcom
previou
mhf
infect
two
cat
adult
spf
cat
moreov
preexperi
male
castrat
spf
cat
use
cat
hous
group
confin
univers
facil
etholog
hygien
ideal
condit
experi
approv
veterinari
offic
canton
zurich
tvb
conduct
accord
swiss
law
fifti
day
prior
plasma
transfus
experiment
infect
spf
statu
cat
confirm
test
absenc
infect
felin
hemoplasma
felin
caliciviru
felin
felin
coronaviru
felin
leukemia
felin
immunodefici
viru
well
bartonella
hensela
chlamydia
feli
recent
describ
absenc
mhf
infect
confirm
realtim
quantit
q
pcr
day
prior
plasma
transfus
mhf
inocul
donor
cat
cat
preexperi
bloodtyp
use
commerci
immunochromatographi
techniqu
felin
lab
test
b
alvedia
franc
recipi
cat
bloodtyp
liberti
research
inc
waverli
standard
salineagglutin
crossmatch
procedur
perform
ascertain
compat
transfus
passiv
immun
total
ml
plasma
collect
three
cat
overcom
previou
mhf
infect
plasma
collect
cat
day
post
mhf
inocul
clear
infect
without
treatment
wherea
receiv
antibiot
treatment
clear
infect
mgkgday
doxycyclin
day
mgkgday
doxycyclin
day
follow
mgkgday
marbofloxacin
day
latter
two
cat
antibiot
treatment
stop
day
prior
plasma
collect
cat
test
neg
mhf
least
eight
consecut
week
follow
antibiot
treatment
prior
plasma
collect
determin
use
weekli
collect
blood
sampl
analyz
triplic
mhfspecif
qpcr
assay
plasma
transfus
control
cat
total
ml
plasma
two
adult
spf
cat
collect
prior
plasma
collect
two
cat
confirm
neg
three
felin
hemoplasma
use
qpcr
free
commonli
known
felin
pathogen
describ
plasma
prepar
whole
blood
collect
donor
cat
jugular
vein
shortdur
gener
anesthesia
mgkg
ketamin
ag
belp
switzerland
mgkg
midazolam
roch
pharma
ag
reinach
switzerland
blood
anticoagul
acidcitratedextros
acd
final
concentr
plasma
separ
rbc
centrifug
min
store
use
prior
transfus
plasma
thaw
pool
pool
plasma
mhfrecov
cat
pool
b
plasma
spf
cat
filter
pores
filter
jet
biofil
madrid
spain
ml
aliquot
prepar
freez
thaw
filtrat
plasma
test
triplic
mhfspecif
qpcr
assay
absenc
mhf
organ
plasma
transfus
recipi
cat
put
shortdur
gener
anesthesia
mgkg
ketamin
ag
mgkg
midazolam
roch
pharma
ag
ml
whole
blood
collect
baselin
analysi
prevent
circulatori
volum
overload
plasma
prewarm
intraven
administ
durat
min
use
standard
blood
transfus
set
micron
utah
medic
product
inc
utah
usa
transfus
cat
close
monitor
transfus
reaction
preexperi
adult
spf
cat
intraven
transfus
ml
aliquot
plasma
pool
later
use
passiv
immun
cat
group
transfus
weekli
blood
sampl
collect
cat
week
analyz
use
mhfspecif
qpcr
main
experi
recipi
cat
assign
two
group
group
n
passiv
immun
cat
group
b
n
control
group
cat
cat
group
hous
togeth
end
studi
period
day
plasma
transfus
perform
cat
experiment
inocul
mhf
passiv
immun
cat
group
transfus
ml
aliquot
plasma
pool
cat
group
b
transfus
ml
aliquot
plasma
pool
b
ten
minut
complet
transfus
cat
group
b
inocul
mhf
subcutan
inject
dimethyl
sulfoxid
dmso
preserv
blood
contain
copi
mhf
dilut
phosphatebuff
salin
pb
previous
describ
aliquot
mhf
inoculum
use
infect
recipi
cat
studi
use
infect
plasma
donor
cat
previou
studi
clinic
condit
bodi
temperatur
bodi
weight
record
blood
sampl
collect
prior
plasma
transfus
mhf
inocul
day
twice
weekli
post
inocul
pi
week
weekli
thereaft
day
pi
addit
blood
collect
measur
red
blood
cell
rbc
osmot
fragil
perform
day
pi
rbc
still
increas
compar
baselin
valu
sever
cat
group
b
day
pi
sampl
collect
without
anesthesia
except
sampl
collect
day
sampl
pcr
analysi
serolog
store
analysi
flow
cytometri
hematolog
blood
biochemistri
coomb
test
rbc
assay
carri
within
h
blood
collect
hematolog
paramet
determin
day
twice
weekli
pi
week
weekli
thereaft
day
pi
sysmex
instrument
sysmex
corpor
kobe
japan
previous
describ
white
blood
cell
differenti
analysi
confirm
use
manual
evalu
wrightgiemsa
stain
blood
smear
sever
anemia
defin
mild
moder
sever
bilirubin
total
protein
albumin
concentr
measur
day
day
pi
weekli
thereaft
day
pi
use
coba
integra
system
roch
diagnost
rotkreuz
switzerland
globulin
valu
calcul
subtract
albumin
valu
total
protein
concentr
refer
interv
mean
standard
deviat
sd
pcv
total
protein
concentr
kitten
week
age
obtain
literatur
bilirubin
concentr
reach
adult
valu
week
age
laboratori
devicespecif
refer
interv
use
paramet
rbc
determin
day
day
pi
use
publish
protocol
refer
interv
determin
nine
healthi
cat
previou
studi
hemolysi
nacl
wv
direct
coomb
test
perform
day
day
pi
rbc
edtaanticoagul
blood
sampl
wash
dilut
nacl
wv
solut
incub
h
felin
antiglobulin
reagent
mp
biomed
llc
solon
ohio
usa
dilut
rang
describ
agglutin
dilut
defin
posit
quantif
mhf
blood
load
qpcr
perform
day
twice
weekli
pi
week
weekli
thereaft
day
pi
total
nucleic
acid
tna
extract
edta
anticoagul
blood
use
magna
pure
lc
roch
diagnost
ag
rotkreuz
switzerland
magna
pure
lc
tna
isol
kit
roch
diagnost
follow
manufactur
instruct
tna
elut
elut
buffer
store
use
batch
extract
neg
control
consist
phosphatebuff
salin
pb
use
monitor
crosscontamin
tna
sampl
test
mhfspecif
qpcr
assay
detect
quantifi
mhf
previous
describ
absolut
quantif
tenfold
serial
dilut
standard
plasmid
use
describ
posit
neg
control
includ
pcr
run
antibodi
recombin
dnak
protein
mhf
measur
day
day
pi
weekli
thereaft
day
pi
use
previous
describ
elisa
serum
dilut
ng
recombin
protein
per
well
use
describ
sampl
collect
one
cat
measur
plate
plate
antigen
coat
within
batch
absorb
measur
wavelength
nm
use
spectramax
plu
micropl
spectrophotomet
molecular
devic
sunnyval
ca
usa
defin
neg
base
dnak
elisa
result
obtain
spf
cat
describ
flow
cytometr
analysi
perform
day
day
pi
three
differ
stain
combin
primari
antibodi
use
fluorescein
isothiocyan
fitc
conjug
mous
antifelin
antibodi
southern
biotech
allschwil
switzerland
rphycoerythrin
rpe
conjug
mous
antifelin
antibodi
abd
serotec
puchheim
germani
fitcconjug
mous
antifelin
antibodi
fitcconjug
mous
antifelin
antibodi
southern
biotech
rpeconjug
rat
antimous
antibodi
abd
serotec
marker
felin
lymphocyt
lymphocyt
repres
helper
cytotox
lymphocyt
respect
lymphocyt
repres
activ
lymphocyt
antibodi
use
identifi
b
lymphocyt
prior
start
experi
antibodi
titrat
optim
dilut
follow
dilut
dilut
undilut
aliquot
edta
anticoagul
blood
incub
aforement
antibodi
rule
nonspecif
bind
isotyp
control
antibodi
rpeconjug
mous
fitcconjug
mous
abd
serotec
unstain
blood
sampl
cat
use
neg
control
blood
sampl
stain
accord
publish
protocol
flow
cytometri
perform
use
guava
flow
cytomet
millipor
darmstadt
germani
use
guavasoft
softwar
gate
repres
lymphocyt
popul
set
base
forward
side
scatter
event
acquir
sampl
absolut
number
lymphocyt
subset
calcul
multipli
absolut
lymphocyt
number
hematolog
subset
percentag
previous
publish
differ
paramet
per
cat
statist
analyz
use
microsoft
excel
version
analyseit
softwar
ltd
leed
uk
graphpad
prism
graphpad
softwar
inc
ca
usa
u
test
pmwu
use
compar
two
group
b
time
point
one
cat
group
b
stay
pcrneg
seroneg
throughout
studi
period
investig
whether
signific
differ
observ
group
b
relat
inclus
cat
u
test
repeat
without
data
cat
signific
paramet
result
analys
report
differ
origin
result
includ
cat
friedman
test
pf
follow
dunn
post
test
pd
use
analyz
paramet
time
two
time
point
consid
multipl
adjust
p
valu
comparison
famili
comparison
comput
fisher
exact
test
use
determin
signific
differ
proport
p
valu
consid
signific
adult
cat
transfus
aliquot
plasma
pool
preexperi
test
mhf
pcrneg
sampl
collect
week
transfus
data
shown
cat
stay
clinic
healthi
throughout
entir
experi
prior
plasma
transfus
experiment
infect
day
cat
group
test
mhf
pcrneg
cat
group
b
becam
mhf
pcrposit
within
day
day
pi
respect
figur
b
except
one
cat
group
b
cat
remain
pcrneg
throughout
followup
period
figur
becam
mhf
pcrposit
end
experi
day
pi
data
shown
peak
hemoplasma
load
group
copiesml
blood
group
b
copiesml
blood
reach
day
pi
group
day
pi
group
b
signific
differ
mhf
blood
load
two
group
followup
period
except
day
pi
group
show
significantli
higher
mhf
blood
load
pmwu
figur
differ
signific
pcrneg
cat
group
b
exclud
analysi
pmwu
cat
group
test
neg
dnak
elisa
defin
prior
plasma
transfus
figur
b
passiv
immun
subsequ
infect
group
cat
show
slightli
significantli
higher
dnak
elisa
valu
day
pi
compar
valu
cat
group
b
pmwu
figur
day
day
pi
signific
differ
dnak
elisa
valu
evid
two
group
cat
exclud
analys
antidnak
antibodi
level
cat
group
still
significantli
higher
earli
passiv
immun
day
pi
pmwu
day
pi
thereaft
day
pi
compar
cat
group
b
signific
differ
time
seroconvers
two
group
cat
group
b
seroconvert
day
pi
except
cat
group
b
develop
antimhf
dnak
antibodi
throughout
studi
figur
two
cat
group
group
b
seroneg
end
experi
figur
one
cat
treat
doxycyclin
day
pi
pronounc
decreas
pack
cell
volum
pcv
day
pi
see
seven
ten
cat
group
becam
moder
anem
pcv
day
pi
figur
group
b
one
cat
show
moder
anemia
pcv
one
cat
sever
anemia
pcv
day
pi
respect
figur
lowest
pcv
observ
studi
found
cat
pcv
day
pi
group
b
signific
differ
mean
pcv
valu
two
group
figur
signific
chang
pcv
time
group
group
pf
group
b
pf
pcv
valu
cat
higher
toward
end
studi
period
compar
first
week
pi
figur
b
find
may
attribut
increas
age
cat
refer
interv
pcv
report
increas
age
week
week
three
cat
group
cat
two
cat
group
b
cat
develop
elev
bodi
temperatur
cours
experi
day
pi
day
pi
day
pi
day
pi
day
pi
addit
apathi
anorexia
weak
observ
three
cat
group
day
pi
day
pi
one
cat
group
b
day
pi
three
cat
necessit
oral
antibiot
treatment
doxycyclin
mgkgday
supracyclin
gmbh
switzerland
day
decis
treat
cat
base
presenc
sever
anemia
group
pcv
day
pi
pronounc
decreas
pcv
within
h
pcv
day
pi
pcv
day
pi
three
cat
show
clinic
sign
apathi
anorexia
weak
fever
treatment
initi
day
rbc
significantli
lower
cat
group
compar
cat
group
b
pmwu
mean
rbc
group
remain
within
refer
interv
group
b
hemolysi
nacl
wv
respect
refer
interv
hemolysi
nacl
wv
figur
thereaft
day
pi
rbc
significantli
higher
cat
group
compar
cat
group
b
pmwu
figur
cat
exclud
analys
longer
signific
differ
group
day
pi
remark
compar
baselin
valu
rbc
still
increas
sever
cat
group
b
day
pi
figur
b
therefor
one
measur
obtain
day
pi
rbc
significantli
chang
cours
infect
cat
group
pf
figur
rbc
reach
maxim
valu
day
pi
eight
ten
anim
group
rang
hemolysi
nacl
wv
day
pi
cat
hemolysi
nacl
wv
day
pi
cat
hemolysi
nacl
wv
figur
cat
group
b
turn
mhf
pcrposit
end
experi
day
pi
show
pronounc
increas
rel
rbc
time
mhf
bacteremia
hemolysi
nacl
wv
day
pi
refer
interv
hemolysi
nacl
wv
figur
cat
group
test
neg
direct
coomb
test
time
point
data
shown
cat
group
show
increas
leukocyt
count
immedi
infect
follow
signific
decreas
nadir
reach
three
four
week
pi
data
shown
signific
differ
leukocyt
count
two
group
followup
period
lymphocyt
cell
count
show
initi
increas
follow
signific
decreas
nadir
reach
day
pi
coincid
onset
peak
bacteremia
cat
group
pf
figur
pattern
less
pronounc
cat
group
b
pf
figur
furthermor
compar
cat
group
b
cat
group
significantli
higher
blood
lymphocyt
count
day
pi
pmwu
well
tendenc
higher
count
day
pi
pmwu
figur
cat
exclud
analys
lymphocyt
cell
count
tend
higher
group
compar
group
b
studi
period
signific
achiev
eosinophil
show
similar
pattern
lymphocyt
count
cat
group
decreas
cell
count
delay
nadir
reach
week
pi
pf
figur
pattern
less
pronounc
cat
group
b
pf
figur
contrast
monocyt
count
increas
infect
cat
group
maxim
valu
reach
day
pi
pf
figur
pattern
less
pronounc
cat
group
b
pf
figur
compar
count
group
b
monocyt
count
group
higher
time
point
pi
signific
reach
day
pi
pmwu
figur
monocyt
cell
count
higher
group
compar
group
b
time
point
pi
cat
exclud
signific
reach
day
pi
pmwu
neutrophil
significantli
chang
time
cat
group
pf
figur
signific
differ
neutrophil
count
two
group
cours
differ
white
blood
cell
subset
compar
cours
pcv
mhf
bacteremia
cat
show
decreas
leukocyt
lymphocyt
neutrophil
cell
count
prior
decreas
pcv
onset
maxim
mhf
blood
load
data
shown
similar
pattern
also
observ
eosinophil
wherea
monocyt
count
peak
onset
maxim
anemia
cat
data
shown
passiv
immun
cat
analyz
lymphocyt
subset
lymphocyt
activ
lymphocyt
b
lymphocyt
show
signific
chang
time
pf
control
cat
signific
chang
cours
infect
observ
activ
lymphocyt
subset
pf
specif
cat
group
show
signific
decreas
lymphocyt
count
nadir
reach
day
pi
respect
coincid
onset
peak
bacteremia
pf
pf
pf
figur
ratio
significantli
increas
week
pi
passiv
immun
cat
pf
figur
cat
group
show
signific
decreas
b
lymphocyt
count
maxim
bacteremia
nadir
reach
day
pi
pf
figur
b
lymphocyt
count
significantli
higher
day
pi
compar
cat
group
b
pmwu
figur
cat
exclud
analys
b
lymphocyt
count
also
higher
cat
group
compar
cat
group
b
signific
reach
day
pi
pmwu
activ
lymphocyt
subset
show
somewhat
differ
pattern
lymphocyt
subset
group
activ
lymphocyt
count
increas
earli
cours
infect
onset
pcrposit
peak
bacteremia
markedli
decreas
reach
nadir
day
pi
pf
pattern
also
present
less
pronounc
group
b
pf
figur
furthermor
compar
cat
group
b
cat
group
show
significantli
higher
activ
lymphocyt
count
day
pi
pmwu
significantli
lower
level
day
pi
pmwu
figur
cat
exclud
analys
tendenc
higher
activ
lymphocyt
count
cat
group
compar
group
b
found
day
pi
pmwu
differ
day
pi
still
signific
lower
count
cat
group
compar
cat
group
b
pmwu
bilirubin
concentr
significantli
increas
group
cours
experi
peak
day
pi
group
pf
group
b
pf
addit
file
bilirubin
concentr
lower
group
group
b
day
pi
pmwu
tend
higher
day
end
experi
signific
reach
day
pi
pmwu
addit
file
mean
bilirubin
concentr
group
remain
within
refer
interv
bilirubin
concentr
throughout
studi
period
bilirubin
concentr
exceed
refer
interv
observ
three
cat
group
dhr
day
pi
day
pi
day
pi
bilirubin
concentr
rang
total
protein
concentr
significantli
chang
time
group
pf
b
pf
addit
file
peak
day
pi
respect
higher
total
protein
concentr
observ
cat
group
compar
cat
group
b
signific
reach
day
pi
pmwu
addit
file
cat
exclud
analys
total
protein
concentr
group
also
higher
compar
cat
group
b
signific
reach
day
pi
pmwu
mean
total
protein
concentr
group
remain
within
refer
interv
total
protein
refer
interv
week
age
gl
throughout
studi
period
total
protein
concentr
refer
interv
observ
two
cat
group
one
cat
group
b
total
protein
concentr
gl
globulin
concentr
significantli
increas
time
group
pf
addit
file
compar
cat
group
b
cat
group
show
significantli
higher
globulin
concentr
day
pi
pmwu
addit
file
first
studi
investig
protect
role
humor
immun
respons
hemoplasma
infect
use
passiv
immun
experi
studi
demonstr
passiv
transfer
antibodi
mhfrecov
spf
cat
prevent
infect
high
bacteri
load
develop
clinic
sign
follow
homolog
challeng
mhf
passiv
immun
control
cat
show
differ
onset
extent
bacteremia
anemia
cours
mhf
infect
hick
et
al
recent
document
mhfrecov
cat
protect
reinfect
follow
rechalleng
homolog
mhf
isol
studi
indic
presenc
antibodi
mhf
mediat
protect
homolog
challeng
cellular
innat
immun
mechan
may
necessari
provid
protect
mhf
infect
also
line
studi
hick
et
al
report
protect
mhf
reinfect
absenc
pronounc
respons
cat
rechalleng
latter
studi
protect
cat
show
increas
antidnak
antibodi
mrna
level
follow
mhf
rechalleng
antidnak
antibodi
level
passiv
immun
cat
higher
first
week
transfus
control
cat
remain
threshold
seroposit
day
pi
possibl
level
antibodi
passiv
immun
cat
follow
transfus
suffici
high
prevent
bacteremia
howev
hick
et
al
document
protect
mhf
although
antibodi
level
dnak
rise
mhf
challeng
infect
remain
rather
low
level
mean
logtransform
rel
antibodi
level
ral
compar
control
cat
de
novomhf
infect
peak
mean
ral
conclud
mhfspecif
antibodi
respons
immun
protect
cat
low
level
antidnak
antibodi
could
suffici
provid
protect
mhf
infect
assay
calcul
use
quantifi
antidnak
antibodi
studi
differ
use
present
studi
direct
comparison
antibodi
titer
possibl
furthermor
need
consid
antibodi
differ
epitop
specif
detect
current
dnak
elisa
could
mediat
immun
protect
howev
assay
measur
antibodi
avail
infect
enhanc
ie
earlier
onset
bacteremia
anemia
recent
document
cat
recov
cmt
infect
rechalleng
mhf
cmtrecov
cat
serolog
posit
mhf
inocul
studi
suggest
preexist
antibodi
cmt
might
enhanc
infect
kinet
cmtrecov
cat
although
infect
kinet
differ
passiv
immun
control
cat
studi
result
still
suggest
transfer
antibodi
mhfrecov
cat
could
potenti
harm
passiv
immun
cat
show
signific
increas
rbc
cours
infect
effect
observ
control
cat
indic
increas
simpli
due
nonspecif
effect
plasma
transfus
rbc
fragil
hypothes
antibodi
bound
mhf
organ
attach
rbc
rbcbound
antibodi
found
primari
mhf
infect
induc
receptormedi
rbc
phagocytosi
activ
complement
system
present
studi
rbcbound
antibodi
detect
cat
coomb
test
sensit
assay
may
limit
bilirubin
concentr
also
higher
passiv
immun
versu
control
cat
time
point
infect
rbc
destruct
lead
format
free
hemoglobin
process
mononuclear
phagocyt
system
process
bilirubin
form
releas
blood
stream
metabol
excret
liver
pronounc
rbc
destruct
capac
liver
metabol
bilirubin
overwhelm
hyperbilirubinemia
occur
hyperbilirubinemia
observ
three
cat
group
although
mean
bilirubin
concentr
group
remain
within
refer
interv
nevertheless
higher
rbc
valu
occasion
higher
bilirubin
concentr
could
point
toward
pronounc
rbc
destruct
passiv
immun
cat
follow
subsequ
mhf
challeng
exposur
passiv
immun
cat
show
sign
pronounc
immun
respons
compar
control
cat
cat
group
show
higher
lymphocyt
monocyt
b
lymphocyt
count
higher
total
protein
globulin
concentr
control
cat
sever
time
point
experi
furthermor
peak
globulin
concentr
coincid
peak
antidnak
antibodi
level
group
result
also
found
recent
studi
document
polyclon
hypergammaglobulinemia
mhf
infect
coincid
high
antidnak
antibodi
specul
larg
portion
immun
globulin
pool
hemoplasmaspecif
potenti
due
polyclon
b
lymphocyt
activ
induct
autoreact
antibodi
recent
report
porcin
hemoplasma
mycoplasma
sui
thought
caus
upregul
b
lymphocyt
respons
chang
rbc
surfac
infect
host
could
argu
use
homolog
mhf
isol
experiment
challeng
recipi
cat
use
infect
plasma
donor
cat
contribut
pronounc
immun
respons
passiv
immun
cat
report
felin
pathogen
ie
felin
coronaviru
fcov
caus
felin
infecti
periton
fip
pathogenesi
fip
viru
target
macrophag
infect
cell
enhanc
presenc
antibodi
antibodydepend
enhanc
ade
takano
et
al
show
cat
passiv
immun
antibodi
serotyp
fcov
show
enhanc
onset
diseas
follow
inocul
homolog
serotyp
found
cat
passiv
immun
antibodi
serotyp
ii
fcov
challeng
serotyp
author
conclud
fcov
reinfect
serotyp
might
induc
ade
could
advanc
develop
fip
although
ade
also
suspect
bacteri
infect
unknown
whether
might
play
role
pathogenesi
felin
hemoplasma
infect
sign
infect
enhanc
recent
document
candidatu
turicensi
recov
seroposit
cat
follow
challeng
mhf
studi
suggest
presenc
antibodi
direct
cmt
could
enhanc
mhf
infect
howev
best
knowledg
diseas
enhanc
rechalleng
felin
hemoplasma
speci
document
contrast
two
studi
show
cat
recov
mhf
cmt
infect
protect
reinfect
follow
rechalleng
hemoplasma
speci
respect
studi
use
aliquot
mhf
cmt
isol
reinfect
use
primari
infect
cat
person
commun
rhl
passiv
immun
cat
show
signific
decreas
lymphocyt
count
near
onset
peak
bacteremia
around
week
pi
compris
decreas
absolut
count
lymphocyt
lymphocyt
b
lymphocyt
around
three
week
pi
follow
increas
lymphocyt
subset
end
studi
two
recent
studi
report
similar
pattern
lymphocyt
subset
follow
mhf
infect
cmtrecov
cat
decreas
explain
migrat
cell
peripher
blood
drain
lymph
node
becom
activ
prolifer
individu
cat
decreas
leukocyt
lymphocyt
neutrophil
count
occur
prior
develop
anemia
onset
peak
bacteremia
similar
pattern
also
observ
eosinophil
wherea
monocyt
count
peak
onset
maxim
anemia
decreas
leukocyt
neutrophil
count
could
caus
increas
consumpt
cell
involv
bacteri
kill
less
like
reduc
product
due
undefin
inhibitori
factor
monocytosi
could
found
due
hemolysi
shown
associ
mhf
infect
natur
infect
cat
document
leukopenia
neutropenia
well
decreas
eosinophil
lymphocyt
increas
monocyt
time
peak
mhf
bacteremia
also
recent
studi
difficult
judg
whether
decreas
white
blood
cell
subset
due
bacteri
replic
cell
consumpt
convers
whether
decreas
white
blood
cell
facilit
bacteri
replic
interestingli
one
cat
group
b
stay
pcrneg
seroneg
followup
period
develop
bacteremia
seroconvert
day
mhf
inocul
although
lowlevel
bacteremia
detect
limit
pcr
assay
complet
exclud
cat
would
expect
product
infect
result
seroconvers
cat
studi
kept
strictli
control
hygien
condit
vectorborn
transmiss
cat
exclud
howev
cat
group
b
hous
togeth
four
five
cat
group
b
test
mhf
pcrposit
time
bacteremia
seroconvers
occur
cat
therefor
direct
transmiss
cat
ie
aggress
interact
seem
like
although
obviou
clinic
sign
aggress
interact
observ
cat
studi
time
experi
direct
transmiss
mhf
saliva
seem
unlik
low
hemoplasma
load
detect
saliva
mhfinfect
cat
transmiss
oral
subcutan
inocul
saliva
success
anoth
felin
hemoplasma
speci
cmt
present
studi
limit
mask
use
data
collect
analysi
furthermor
rel
small
group
size
use
studi
anim
welfar
reason
could
mask
signific
differ
passiv
immun
control
cat
howev
protect
rather
sign
infect
enhanc
found
passiv
immun
cat
limit
group
size
affect
princip
hypothesi
address
studi
present
studi
use
experiment
setup
address
protect
role
passiv
transfer
antibodi
mhf
infect
experiment
infect
studi
inher
limit
result
gener
natur
infect
howev
mirror
natur
transmiss
hemoplasma
accur
publish
lowdos
infect
model
appli
studi
inocul
dose
contain
copi
mhf
correspond
approxim
infecti
blood
natur
infect
cat
small
blood
volum
easili
transmit
bloodsuck
arthropod
via
aggress
interact
latter
transmiss
rout
assum
natur
way
transmiss
felin
hemoplasma
therefor
infecti
dose
appli
cat
reason
lack
protect
passiv
immun
cat
sever
measur
undertaken
ensur
plasma
use
passiv
immun
contain
viabl
mhf
organ
could
transmit
infect
donor
cat
test
weekli
least
eight
consecut
week
plasma
collect
sampl
plasma
pool
test
triplic
highli
sensit
mhfspecif
qpcr
assay
reveal
pcrneg
result
furthermor
aliquot
plasma
pool
use
passiv
immun
transfus
adult
spf
cat
follow
week
transfus
stay
pcrneg
conclus
passiv
immun
provid
protect
experiment
infect
mhf
instead
enhanc
rbc
fragil
associ
pronounc
immun
respons
infect
result
suggest
humor
immun
respons
absenc
cellular
immun
mechan
insuffici
provid
protect
mhf
infect
potenti
vaccin
candid
includ
induct
cellular
immun
respons
mhf
